Table 4 PCR corrected efficacy of AN vs Duocotecxin in all malaria, Indonesia
Outcome | Artemisinin- naphthoquine (AN) | Dihydroartemisinin-piperaquine (DHP) | P | Overall |
|---|---|---|---|---|
ACPR/Treatment Success (%, 95% CL) | ||||
ITT | 181 [90.0 (85.9–94.2)] | 180 [90.0 (85.8–94.2)] | 0.99 | 361 [90.0 (86.7–92.8)] |
Modified ITT | 181 [93.3 (89.8–96.8)] | 180 [94.7 (91.6–97.9)] | 0.55 | 361 [94.0 (91.1–96.2)] |
Per Protocol | 181 [96.3 (93.6–99.0)] | 180 [97.3 (95.0–99.6)] | 0.58 | 361 [96.8 (94.4–98.3)] |
Late Clinical Failure-LCF (%, 95% CL) | ||||
ITT | 4 [2.0 (0.1–3.9)] | 1 [0.5 (0.5–1.5)] | 0.18 | 5 [1.2 (0.4–2.9)] |
Modified ITT | 4 [2.1 (0.1–4.1)] | 1 [0.5 (0.5–1.6)] | 0.18 | 5 [1.3 (0.4–3.0)] |
3. Per Protocol | 4 [2.1 (0.1–4.2)] | 1 [0.5 (0.5–1.6)] | 0.18 | 5 [1.3 (0.4–3.1)] |
Late Parasitological Failure-LPF (%, 95% CL) | ||||
ITT | 3 [1.5 (0.2–3.2)] | 4 [2.0 (0.1–3.9)] | 0.70 | 7 [1.7 (0.7–3.6)] |
Modified ITT | 3 [1.6 (0.2–3.3)] | 4 [2.1 (0.1–4.1)] | 0.68 | 7 [1.8 (0.7–3.7)] |
Per Protocol | 3 [1.6 (0.2–3.4)] | 4 [2.2 (0.1–4.3)] | 0.69 | 7 [1.9 (0.8–3.8)] |
“Other Failures” (%, 95% CL) | ||||
ITT | 13 [6.5 (3.1–9.9)] | 15 [7.5 (3.8–11.1)] | 0.68 | 28 [7.0 (4.7–9.9)] |
Modified ITT | 6 [3.1 (0.7–5.5)] | 5[2.6 (0.4–4.9)] | 11 [2.9 (1.4–5.1)] | |
Per Protocol | 0 | 0 | 0.79 | 0 |